Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As VC Investments Rebound In Q2, Skepticism Lingers

This article was originally published in The Pink Sheet Daily

Executive Summary

A quarterly report shows an uptick in VC disbursements, but LP commitments are still lagging.

You may also be interested in...



Financings Of The Fortnight Sees More Conflicting Indicators For Biotech VC

Quarterly trends suggest the outlook may turn sunny, plus financings updates on NuPathe, Euthymics Bioscience, Xoma and Immune Design Corp.

Financings Of The Fortnight Sees More Conflicting Indicators For Biotech VC

Quarterly trends suggest the outlook may turn sunny, plus financings updates on NuPathe, Euthymics Bioscience, Xoma and Immune Design Corp.

Euthymics' Sweet Dreams Could Be Realized With $24MM Series A

The startup will resume trials on a novel antidepressant lost in the shuffle when DOV Pharmaceuticals ceased operations.

Related Content

Topics

UsernamePublicRestriction

Register

PS070907

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel